Skip to main content
SpringerLink
Log in

Single nucleotide polymorphisms and expression of ERCC1 and ERCC2 vis-à-vis chemotherapy drug cytotoxicity in human glioma

  • LAB INVESTIGATION
  • Published:
Journal of Neuro-Oncology Aims and scope Submit manuscript

Abstract

ERCC1 and ERCC2 have been known to belong to the nucleotide excision repair (NER) pathway and are essential to the repair of cisplatin DNA adducts. In the present study, we have examined the potential correlation of ERCC1, ERCC2 mRNA expression and single nucleotide polymorphism (SNP) to chemotherapy drug cytotoxicity from 49 human gliomas. Fresh human glioma specimens were obtained during surgery. SNPs of ERCC1 and ERCC2 was determined by single strand conformation polymorphism (SSCP) and sequencing. ERCC1 and ERCC2 expression was quantified using real-time quantitative reverse transcription-PCR. Chemotherapy drug cytotoxicity was determined by the tetrazolium (MTT) assay for cisplatin (CDDP), 1,3-bis-(2-chloroethyl)-1-nitrosourea (BCNU), vincristine (VCR) and teniposide (VM26). The results show that there was no statistically significant association between the C8092A polymorphism of ERCC1 or codon 312 and codon 751 polymorphisms of ERCC2 and the chemotherapy drug cytotoxicity. However there was a strong correlation between ERCC1 and ERCC2 mRNA expression levels (Spearman r = 0.42; P < 0.003). Further more, tumor samples with low ERCC1 mRNA expression levels showed enhanced CDDP cytotoxicity (P = 0.0001) while ERCC2 expression was reversely correlated with BCNU cytotoxicity (P = 0.004). In sum, Our results indicated that ERCC1 mRNA expression is associated with CDDP cytotoxicity and ERCC2 mRNA levels is related with BCNU cytotoxicity, while there was no correlation between SNP of ERCC1, ERCC2 and in vitro cytotoxicity of four anticancer drugs, CDDP, BCNU, VCR and VM26.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Abbreviations

BCNU:

1,3-bis-(2-chloroethyl)-1-nitrosourea

CDDP:

Cisplatin

DMSO:

Dimethylsulfoxide

ERCC1:

Excision repair cross complementing protein 1

ERCC2:

Excision repair cross complementing protein 2

HDRA:

Histoculture drug response assay

MTT:

Tetrazolium

NSCLC:

Non-small cell lung cancer

NER:

Nucleotide excision repair

PPC:

Peak plasma concentration

SNP:

Single nucleotide polymorphism

SSCP:

Single strand conformation polymorphism

SarCNU:

(2-chloroethyl)-3-sarcosinamide-1-nitrosourea

VCR:

Vincristine

VM26:

Teniposide

Reference

  1. Furukawa T KT, Hoffman RM (1995) Clinical applications of the histoculture drug response assay. Clin Cancer Res 1(3):305–311

    PubMed  CAS  Google Scholar 

  2. Hoffman R (1991) In vitro sensitivity assays in cancer: a review, analysis and prognosis. J Clin Lab Anal 5:133

    Article  PubMed  CAS  Google Scholar 

  3. Suda S AS, Sekiguchi H, Kasai Y, Ito K, Nakao A (2002) Evaluation of the histoculture drug response assay as a sensitivity test for anticancer agents. Surg Today 32(6):477–481

    Article  PubMed  CAS  Google Scholar 

  4. Furuta T, Ueda T, Aune G, Sarasin A, Kraemer KH, Pommier Y (2002) Transcription-coupled nucleotide excision repair as a determinant of cisplatin sensitivity of human cells. Cancer Res 62(17):4899–4902

    PubMed  CAS  Google Scholar 

  5. Yu JJ, Lee KB, Mu C, Li Q, Abernathy TV, Bostick-Bruton F, Reed E (2000) Comparison of two human ovarian carcinoma cell lines (A2780/CP70 and MCAS) that are equally resistant to platinum, but differ at codon 118 of the ERCC1 gene. Int J Oncol 16(3):555–560

    PubMed  CAS  Google Scholar 

  6. Metzger R, Leichman CG, Danenberg KD, Danenberg PV, Lenz HJ, Hayashi K, Groshen S, Salonga D, Cohen H, Laine L, et al (1998) ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy. J Clin Oncol 16(1):309–316

    PubMed  CAS  Google Scholar 

  7. Simon GR, Sharma S, Cantor A, Smith P, Bepler G (2005) ERCC1 expression is a predictor of survival in resected patients with non-small cell lung cancer. Chest 127(3):978–983

    Article  PubMed  Google Scholar 

  8. Rosell R, Lord RV, Taron M, Reguart N (2002) DNA repair and cisplatin resistance in non-small-cell lung cancer. Lung Cancer 38(3):217–227

    Article  PubMed  Google Scholar 

  9. Aloyz R, Xu ZY, Bello V, Bergeron J, Han FY, Yan Y, Malapetsa A, Alaoui-Jamali MA, Duncan AM, Panasci L (2002) Regulation of cisplatin resistance and homologous recombinational repair by the TFIIH subunit XPD. Cancer Res 62(19):5457–5462

    PubMed  CAS  Google Scholar 

  10. Chen ZP, Malapetsa A, Marcantonio D, Mohr G, Brien S, Panasci LC (1996) Correlation of chloroethylnitrosourea resistance with ERCC-2 expression in human tumor cell lines as determined by quantitative competitive polymerase chain reaction. Cancer Res 56(11):2475–2478

    PubMed  CAS  Google Scholar 

  11. Weaver DA, Crawford EL, Warner KA, Elkhairi F, Khuder SA, Willey JC (2005) ABCC5, ERCC2, XPA and XRCC1 transcript abundance levels correlate with cisplatin chemoresistance in non-small cell lung cancer cell lines. Mol Cancer 4(1):18

    Article  PubMed  CAS  Google Scholar 

  12. Dabholkar M, Bostick-Bruton F, Weber C, Egwuagu C, Bohr VA, Reed E (1993) Expression of excision repair genes in non-malignant bone marrow from cancer patients. Mutat Res 293(2):151–160

    PubMed  CAS  Google Scholar 

  13. Sheibani N, Eastman A (1990) Analysis of various mRNA potentially involved in cisplatin resistance of murine leukemia L1210 cells. Cancer Lett 52(3):179–185

    Article  PubMed  CAS  Google Scholar 

  14. Vogel U, Dybdahl M, Frentz G, Nexo BA (2000) DNA repair capacity: inconsistency between effect of over-expression of five NER genes and the correlation to mRNA levels in primary lymphocytes. Mutat Res 461(3):197–210

    PubMed  CAS  Google Scholar 

  15. Hu G MB, Stensland HMFR, et al (2002) Efficient discovery of single-nuceotide polymorphisms in coding regions of human gene. Pharmacogenomics J 2:236–242

    Article  PubMed  CAS  Google Scholar 

  16. Shen MR, Jones IM, Mohrenweiser H (1998) Nonconservative amino acid substitution variants exist at polymorphic frequency in DNA repair genes in healthy humans. Cancer Res 58(4):604–608

    PubMed  CAS  Google Scholar 

  17. Caggana M, Kilgallen J, Conroy JM, Wiencke JK, Kelsey KT, Miike R, Chen P, Wrensch MR (2001) Associations between ERCC2 polymorphisms and gliomas. Cancer Epidemiol Biomarkers Prev 10(4):355–360

    PubMed  CAS  Google Scholar 

  18. Chen P, Wiencke J, Aldape K, Kesler-Diaz A, Miike R, Kelsey K, Lee M, Liu J, Wrensch M (2000) Association of an ERCC1 polymorphism with adult-onset glioma. Cancer Epidemiol Biomarkers Prev 9(8):843–847

    PubMed  CAS  Google Scholar 

  19. Yu JJ, Mu C, Lee KB, Okamoto A, Reed EL, Bostick-Bruton F, Mitchell KC, Reed E (1997) A nucleotide polymorphism in ERCC1 in human ovarian cancer cell lines and tumor tissues. Mutat Res 382(1–2):13–20

    PubMed  CAS  Google Scholar 

  20. Zhou W, Gurubhagavatula S, Liu G, Park S, Neuberg DS, Wain JC, Lynch TJ, Su L, Christiani DC (2004) Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced non-smallcell lung cancer patients treated with platinum-based chemotherapy. Clin Cancer Res 10(15):4939–4943

    Article  PubMed  CAS  Google Scholar 

  21. Rosell R, Taron M, Camps C, Lopez-Vivanco G (2003) Influence of genetic markers on survival in non-small cell lung cancer. Drugs Today (Barc) 39(10):775–786

    Article  CAS  Google Scholar 

  22. Stoehlmacher J, Park DJ, Zhang W, Yang D, Groshen S, Zahedy S, Lenz HJ (2004) A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer. Br J Cancer 91(2):344–354

    PubMed  CAS  Google Scholar 

  23. Zhang JY, Chen ZP (2003) In vitro chemotherapy drug sensitivity test in human malignant brain tumor. Guangdong Medicine 24(7):715–717

    CAS  Google Scholar 

  24. Sloan AE, Dansey R, Zamorano L, Barger G, Hamm C, Diaz F, Baynes R, Wood G (2000) Adoptive immunotherapy in patients with recurrent malignant glioma: preliminary results of using autologous whole-tumor vaccine plus granulocyte-macrophage colony-stimulating factor and adoptive transfer of anti-CD3-activated lymphocytes. Neurosurg Focus 9(6):e9

    Article  PubMed  CAS  Google Scholar 

  25. Altaha R, Liang X, Yu JJ, Reed E (2004) Excision repair cross complementing-group 1: gene expression and platinum resistance. Int J Mol Med 14(6):959–970

    PubMed  CAS  Google Scholar 

  26. Park DJ, Stoehlmacher J, Zhang W, Tsao-Wei DD, Groshen S, Lenz HJ (2001) A Xeroderma pigmentosum group D gene polymorphism predicts clinical outcome to platinum-based chemotherapy in patients with advanced colorectal cancer. Cancer Res 61(24):8654–8658

    PubMed  CAS  Google Scholar 

  27. Mort R, Mo L, McEwan C, Melton DW (2003) Lack of involvement of nucleotide excision repair gene polymorphisms in colorectal cancer. Br J Cancer 89(2):333–337

    Article  PubMed  CAS  Google Scholar 

  28. Duell EJ, Wiencke JK, Cheng TJ, Varkonyi A, Zuo ZF, Ashok TD, Mark EJ, Wain JC, Christiani DC, Kelsey KT (2000) Polymorphisms in the DNA repair genes XRCC1 and ERCC2 and biomarkers of DNA damage in human blood mononuclear cells. Carcinogenesis 21(5):965–971

    Article  PubMed  CAS  Google Scholar 

  29. Cheng L, Guan Y, Li L, Legerski RJ, Einspahr J, Bangert J, Alberts DS, Wei Q (1999) Expression in normal human tissues of five nucleotide excision repair genes measured simultaneously by multiplex reverse transcription-polymerase chain reaction. Cancer Epidemiol Biomarkers Prev 8(9):801–807

    PubMed  CAS  Google Scholar 

  30. Chen ZP, McQuillan A, Mohr G, Panasci LC (1998) Excision repair cross-complementing rodent repair deficiency gene 2 expression and chloroethylnitrosourea resistance in human glioma cell lines. Neurosurgery 42(5):1112–1119

    Article  PubMed  CAS  Google Scholar 

  31. Chen ZP, Malapetsa A, McQuillan A, Marcantonio D, Bello V, Mohr G, Remack J, Brent TP, Panasci LC (1997) Evidence for nucleotide excision repair as a modifying factor of O6-methylguanine-DNA methyltransferase-mediated innate chloroethylnitrosourea resistance in human tumor cell lines. Mol Pharmacol 52(5):815–820

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. State Key Laboratory of Oncology in Southern China, Cancer Center, Sun Yat-sen University, Guangzhou, 510060, China

    Huayun Chen, Cuijie Shao, Hongliu Shi, Yonggao Mu, Ke Sai & Zhongping Chen

  2. Department of Neurosurgery/Neuro-oncology, Cancer Center, Sun Yet-sen Univerisity, Dongfeng Road East 651, Guangzhou, 510060, P. R. China

    Huayun Chen, Cuijie Shao, Hongliu Shi, Yonggao Mu, Ke Sai & Zhongping Chen

Authors
  1. Huayun Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Cuijie Shao
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hongliu Shi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yonggao Mu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ke Sai
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Zhongping Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Zhongping Chen.

Additional information

This work was supported by National Nature Science Foundation of China No. 30271329

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chen, H., Shao, C., Shi, H. et al. Single nucleotide polymorphisms and expression of ERCC1 and ERCC2 vis-à-vis chemotherapy drug cytotoxicity in human glioma. J Neurooncol 82, 257–262 (2007). https://doi.org/10.1007/s11060-006-9290-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11060-006-9290-2

Keywords

Search

Navigation